当前位置: 首页 >> 检索结果
1101. EUS-guided drainage of large walled-off pancreatic necroses using plastic versus lumen-apposing metal stents: a single-centre randomised controlled trial.
作者: John Gásdal Karstensen.;Srdan Novovic.;Erik Feldager Hansen.;Annette Bojer Jensen.;Henrik Lovendahl Jorgensen.;Morten Laksafoss Lauritsen.;Mikkel Parsberg Werge.;Palle Nordblad Schmidt.
来源: Gut. 2023年72卷6期1167-1173页
In treating pancreatic walled-off necrosis (WON), lumen-apposing metal stents (LAMS) have not proven superior to the traditional double pigtail technique (DPT). Among patients with large WON (>15 cm) and their associated substantial risk of treatment failure, the increased drainage capacity of a novel 20-mm LAMS might improve clinical outcomes. Hence, we conducted a study comparing the DPT and 20-mm LAMS in patients with large WON.
1102. Transcriptomic and immunophenotypic profiling reveals molecular and immunological hallmarks of colorectal cancer tumourigenesis.
作者: Jessica Roelands.;Manon van der Ploeg.;Marieke E Ijsselsteijn.;Hao Dang.;Jurjen J Boonstra.;James C H Hardwick.;Lukas J A C Hawinkels.;Hans Morreau.;Noel F C C de Miranda.
来源: Gut. 2023年72卷7期1326-1339页
Biological insights into the stepwise development and progression of colorectal cancer (CRC) are imperative to develop tailored approaches for early detection and optimal clinical management of this disease. Here, we aimed to dissect the transcriptional and immunologic alterations that accompany malignant transformation in CRC and to identify clinically relevant biomarkers through spatial profiling of pT1 CRC samples.
1103. Crohn's-associated invariant T cells (CAITs) recognise small sulfonate molecules on CD1d.
作者: Anastasia A Minervina.;Mikhail V Pogorelyy.;Steffen Paysen.;Ulrich Luening.;Frauke Degenhardt.;Andre Franke.;Paul G Thomas.;Elisa Rosati.
来源: Gut. 2023年73卷1期205-206页 1105. Response to: Correspondence on 'On the ethics of digestive health research in historically marginalised communities' by Velez and Targownick.
作者: Emad Mansoor.;Scott A Martin.;Abe Perez.;Vu Quang Nguyen.;Jeffry Katz.;Shubham Gupta.;Fabio Cominelli.
来源: Gut. 2023年72卷12期2388页 1108. Health-code-based triage versus universal COVID-19 PCR testing before endoscopy in a low incidence area: a real-world experience.
作者: Zhihui Duan.;Dengxiang Liu.;Shengyun Zhou.;Hui Li.;Xiaofang Sun.;Chunqian Zhao.;Qiong Duan.;Liwei Li.;Xiaochong Zhang.;Lingxuan Jin.
来源: Gut. 2023年72卷2期223-225页 1109. Gut microbiota as non-invasive diagnostic and prognostic biomarkers for natural killer/T-cell lymphoma.
作者: Zhuangzhuang Shi.;Guoru Hu.;Min W Li.;Lei Zhang.;Xin Li.;Ling Li.;Xinhua Wang.;Xiaorui Fu.;Zhenchang Sun.;Xudong Zhang.;Li Tian.;Zhaoming Li.;Wei-Hua Chen.;Mingzhi Zhang.
来源: Gut. 2023年72卷10期1999-2002页 1111. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
作者: Heinz Zoller.;Myles Wolf.;Irina Blumenstein.;Christian Primas.;Stefan Lindgren.;Lars L Thomsen.;Walter Reinisch.;Tariq Iqbal.
来源: Gut. 2023年72卷4期644-653页
Intravenous iron-a common treatment for anaemia and iron deficiency due to inflammatory bowel disease (IBD)-can cause hypophosphataemia. This trial compared the incidence of hypophosphataemia after treatment with ferric carboxymaltose (FCM) or ferric derisomaltose (FDI).
1112. Longitudinal transkingdom gut microbial approach towards decompensation in outpatients with cirrhosis.
作者: Jasmohan S Bajaj.;Marcela Peña-Rodriguez.;Alex La Reau.;Wendy Phillips.;Michael Fuchs.;Brian C Davis.;Richard K Sterling.;Masoumeh Sikaroodi.;Andrew Fagan.;Amirhossein Shamsaddini.;Zachariah Henseler.;Tonya Ward.;Puneet Puri.;Hannah Lee.;Patrick M Gillevet.
来源: Gut. 2023年72卷4期759-771页
First decompensation development is a critical milestone that needs to be predicted. Transkingdom gut microbial interactions, including archaeal methanogens, may be important targets and predictors but a longitudinal approach is needed.
1115. Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding.
作者: Marika Rudler.;Virginia Hernández-Gea.;Bogdan Dumitru Procopet.;Alvaro Giráldez.;Lucio Amitrano.;Càndid Villanueva.;Luis Ibañez.;Gilberto Silva-Junior.;Joan Genesca.;Christophe Bureau.;Jonel Trebicka.;Rafael Bañares.;Aleksander Krag.;Elba Llop.;Wim Laleman.;Jose Maria Palazon.;Jose Castellote.;Susana Rodrigues.;Lise Lotte Gluud.;Carlos Noronha Ferreira.;Nouria Canete.;Manuel Rodríguez.;Arnulf Ferlitsch.;Jose Luis Mundi.;Henning Gronbaek.;Manuel Hernandez-Guerra.;Romano Sassatelli.;Alessandra Dell'era.;Marco Senzolo.;Juan G Abraldes.;Manuel Romero-Gómez.;Alexander Zipprich.;Meritxell Casas.;Helena Masnou.;Hélène Larrue.;Massimo Primignani.;Frederik Nevens.;Jose Luis Calleja.;Remy Schwarzer.;Christian Jansen.;Marie-Angèle Robic.;Irene Conejo.;Javier Martínez Gonzalez.;Maria Vega Catalina.;Agustín Albillos.;Edilmar Alvarado.;Maria Anna Guardascione.;Maxime Mallet.;Simona Tripon.;Georgina Casanovas.;Jaume Bosch.;Juan-Carlos Garcia-Pagan.;Dominique Thabut.; .
来源: Gut. 2023年72卷4期749-758页
A pre-emptive transjugular intrahepatic portosystemic shunt (pTIPS) reduces mortality in high-risk patients with cirrhosis (Child-Pugh C/B+active bleeding) with acute variceal bleeding (AVB). Real-life studies point out that <15% of patients eligible for pTIPS ultimately undergo transjugular intrahepatic portosystemic shunt (TIPS) due to concerns about hepatic encephalopathy (HE). The outcome of patients undergoing pTIPS with HE is unknown. We aimed to (1) assess the prevalence of HE in patients with AVB; (2) evaluate the outcome of patients presenting HE at admission after pTIPS; and (3) determine if HE at admission is a risk factor for death and post-TIPS HE.
1117. Reply to Newman et al 'Response to epidemiology of inflammatory bowel disease in men with high-risk homosexual activity'.
作者: Emad Mansoor.;Scott A Martin.;Abe Perez.;Vu Quang Nguyen.;Jeffry A Katz.;Shubham Gupta.;Fabio Cominelli.
来源: Gut. 2023年72卷11期2187-2188页 1120. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance.
作者: Chao-Yang Meng.;Shiyu Sun.;Yong Liang.;Hairong Xu.;Chao Zhang.;Min Zhang.;Fu-Sheng Wang.;Yang-Xin Fu.;Hua Peng.
来源: Gut. 2023年72卷8期1544-1554页
The purpose of this study is to develop an anti-PDL1-based interferon (IFN) fusion protein to overcome the chronic hepatitis B virus (HBV)-induced immune tolerance, and combine this immunotherapy with a HBV vaccine to achieve the functional cure of chronic hepatitis B (CHB) infection.
|